“We acknowledge there are significant challenges involved in securing reimbursement for innovative medicines in Australia, and our focus in the near term is on enabling private access so patients are not left waiting without options," said Manny Simons, General Manager of Lilly Australia and New Zealand. …
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
May 5, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
La Trobe launches REACH program to fight antimicrobial resistance
May 6, 2026 - - Latest News -
If the imperative is international comparison, why limit it to these definitions?
May 5, 2026 - - Latest News -
Therapy funded three years after the 'clunky' and 'preventable deaths' admission
May 5, 2026 - - Latest News -
Time to make this 'targeted' consultation a little less targeted
May 5, 2026 - - Latest News -
Australia approves first in class therapy for chronic graft versus host disease
May 5, 2026 - - Latest News -
Lilly therapy approved in Australia as first non-covalent BTK inhibitor for common blood cancer
May 5, 2026 - - Latest News -
Medicines Australia calls for transparency, highlighting the risk of bias
May 5, 2026 - - Latest News